At SERG, we have developed novel sensors that are designed to provide objective and accurate measurements of symptom severity. Our clinicians will use this information, in addition to frequent updates from you through our platform, to continuously optimise your treatment, minimising symptom presentation.
In a perfect world, your neurologist would know exactly how your symptoms are affecting you, and could provide prompt support to give you the best quality of life. We have built the PD Ignite platform to manifest this ideal, and hope that you will join us on this journey.
We are delighted to be running the first-ever large-scale trial of the PD Ignite platform in the UK. The study aims to work with people with Parkinson's to correlate changes between their movement and current symptom state using highly personalised custom sensors and wearable technology. By doing this, we will be able to obtain a continuous image of whether an individual is undermedicated or overmedicated. The study also includes a preliminary trial of the PD Ignite Healthcare solution. While this will initially be in collaboration with the person with Parkinson's neurologist, our aim is to offer an additional solution which allows the neurologist to focus on the big-picture treatment plan whilst we look after day-to-day medication adjustments. This new form of personalised care is enabled by technology that is the culmination of nearly a decade of research at Imperial College London. We are delighted to be able to build upon this work to have a positive influence on people's health.
We are currently running this trial at two of the UK's leading NDMD and Parkinson's hospitals.
people tested the system in the clinic.
people have tested the system at home.
Peripheral Neural Stimulation (PNS for short) is a novel method of suppressing tremor is currently gaining popularity. It relies on using tiny, imperceptible electrical stimulation on the surface of the skin to interrupt the signal from the brain which is causing the tremor. Our novel sensors allow us to see exactly how this interaction takes place. We are using this data to develop a wearable stimulation system which will be able to detect and interrupt tremor as it emerges. Our preliminary study showed a reduction in tremor of 30% in a clinical environment. This trial aims to increase this reduction while also increasing the robustness of the system, enabling it to work anywhere at any time.
We are currently running this trial at two of the UK's leading NDMD and Parkinson's hospitals.
people tested the system in the clinic.
Your e-mail address will only be used to send you our newsletter and information about the activities of SERG Technologies. If you no longer wish to receive any emails from us, you can use the unsubscribe link included in the newsletter.